303 related articles for article (PubMed ID: 19531929)
1. Continuous antiretroviral therapy decreases bone mineral density.
Grund B; Peng G; Gibert CL; Hoy JF; Isaksson RL; Shlay JC; Martinez E; Reiss P; Visnegarwala F; Carr AD;
AIDS; 2009 Jul; 23(12):1519-29. PubMed ID: 19531929
[TBL] [Abstract][Full Text] [Related]
2. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy.
Carr A; Grund B; Schwartz AV; Avihingsanon A; Badal-Faesen S; Bernadino JI; Estrada V; La Rosa A; Mallon P; Pujari S; White D; Wyman Engen N; Ensrud K; Hoy JF;
HIV Med; 2020 Jan; 21(1):64-70. PubMed ID: 31642586
[TBL] [Abstract][Full Text] [Related]
3. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A;
J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589
[TBL] [Abstract][Full Text] [Related]
4. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
Kwak MK; Lee EJ; Park JW; Park SY; Kim B-; Kim TH; Suh K; Koh J-; Lee SH; Byun D-
Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
[TBL] [Abstract][Full Text] [Related]
5. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Carr A; Grund B; Neuhaus J; Schwartz A; Bernardino JI; White D; Badel-Faesen S; Avihingsanon A; Ensrud K; Hoy J;
HIV Med; 2015 Apr; 16 Suppl 1(0 1):137-46. PubMed ID: 25711332
[TBL] [Abstract][Full Text] [Related]
7. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
[TBL] [Abstract][Full Text] [Related]
8. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.
Hoy J; Grund B; Roediger M; Ensrud KE; Brar I; Colebunders R; Castro ND; Johnson M; Sharma A; Carr A;
J Bone Miner Res; 2013 Jun; 28(6):1264-74. PubMed ID: 23299909
[TBL] [Abstract][Full Text] [Related]
9. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
10. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
[TBL] [Abstract][Full Text] [Related]
12. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.
Grant PM; Kitch D; McComsey GA; Dube MP; Haubrich R; Huang J; Riddler S; Tebas P; Zolopa AR; Collier AC; Brown TT
Clin Infect Dis; 2013 Nov; 57(10):1483-8. PubMed ID: 23943825
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
[TBL] [Abstract][Full Text] [Related]
14. Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women.
Calmy A; Chevalley T; Delhumeau C; Toutous-Trellu L; Spycher-Elbes R; Ratib O; Zawadynski S; Rizzoli R
Osteoporos Int; 2013 Jun; 24(6):1843-52. PubMed ID: 23138338
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification.
Grampp S; Genant HK; Mathur A; Lang P; Jergas M; Takada M; Glüer CC; Lu Y; Chavez M
J Bone Miner Res; 1997 May; 12(5):697-711. PubMed ID: 9144335
[TBL] [Abstract][Full Text] [Related]
16. Thoracic Quantitative Computed Tomography (QCT) Can Sensitively Monitor Bone Mineral Metabolism: Comparison of Thoracic QCT vs Lumbar QCT and Dual-energy X-ray Absorptiometry in Detection of Age-relative Change in Bone Mineral Density.
Mao SS; Li D; Syed YS; Gao Y; Luo Y; Flores F; Child J; Cervantes M; Kalantar-Zadeh K; Budoff MJ
Acad Radiol; 2017 Dec; 24(12):1582-1587. PubMed ID: 28844601
[TBL] [Abstract][Full Text] [Related]
17. Influence of anthropometric parameters and bone size on bone mineral density using volumetric quantitative computed tomography and dual X-ray absorptiometry at the hip.
Guglielmi G; van Kuijk C; Li J; Meta MD; Scillitani A; Lang TF
Acta Radiol; 2006 Jul; 47(6):574-80. PubMed ID: 16875335
[TBL] [Abstract][Full Text] [Related]
18. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
[TBL] [Abstract][Full Text] [Related]
19. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
[TBL] [Abstract][Full Text] [Related]
20. Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.
Kalayjian RC; Albert JM; Cremers S; Gupta SK; McComsey GA; Klingman KL; Fichtenbaum CJ; Brown TT; Taiwo BO;
AIDS; 2018 Nov; 32(17):2517-2524. PubMed ID: 30134291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
